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Abstract
Genes that cause cancer have been divided into two general classes – oncogenes that act in a
dominant fashion to transform normal cells into a malignant state, and tumor suppressor genes that
act in a dominant fashion to prevent such transformation. In this report, we demonstrate that both
the v-myb retroviral oncogene, which causes leukemic transformation of hematopoietic cells, and
the c-myb proto-oncogene can also function as inhibitors of fibroblast transformation by the v-rel
oncogene. These results imply that the myb genes can function either as oncogenes or as tumor
suppressors in different cellular contexts.
Background
The oncogenic transformation of normal cells of verte-
brates is a multi-step process in which mutations accumu-
late in two classes of cellular genes, oncogenes and tumor
suppressor genes [1]. Oncogenes are altered forms of nor-
mal cellular proto-oncogenes that act in a dominant fash-
ion to convert normal cells into a malignant state. In
contrast, tumor suppressor mutants act in a recessive fash-
ion within the cell and, in general, one wild type copy of
a tumor suppressor gene is sufficient to inhibit transfor-
mation.
The v-myb oncogene of the avian myeloblastosis virus is
unusual because unlike other known oncogenes, it causes
only leukemias in animals and transforms only hemat-
opoietic cells and not fibroblasts in culture [2]. Members
of the Myb protein family bind to specific DNA
sequences, can directly regulate gene expression, and have
been highly conserved during eukaryotic evolution [3].
The myb oncogene has previously been shown to cooper-
ate with the v-ets  oncogene in the transformation of
hematopoietic cells [4]. Indeed, the ets gene family was
initially discovered because of the presence of both v-myb
and v-ets within a single acutely transforming retrovirus,
the E26 leukemia virus [5].
The v-rel oncogene of the avian reticuloendotheliosis virus
strain T (REV-T) causes a malignant proliferation of
immature lymphoid cells in animals and can transform
both lymphoid and fibroblastic cells in culture [6]. How-
ever, fibroblast transformation by this virus is somewhat
weaker than that caused by a variety of other oncogenes
[7]. Members of the Rel protein family include Drosophila
Dorsal and vertebrate NF-kB, and like Myb, these proteins
bind to specific DNA sequences and can directly regulate
gene expression [8]. In order to test whether v-myb and c-
myb could cooperate with v-rel in oncogenic transforma-
tion of hematopoietic cells, we constructed a series of
avian retroviruses that coexpress either one or both of
these oncogenes. Quite unexpectedly, we found that v-
myb and c-myb suppress fibroblast transformation by v-rel.
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Results and discussion
v-Myb and c-Myb inhibit fibroblast transformation by v-
Rel-ER
To insure the efficient production of both Rel and Myb
proteins in the same cell by viruses containing two onco-
genes, we have used an internal ribosomal entry site
(IRES) from the encephalomyocarditis virus to permit
translation of both proteins from a single mRNA (Figure
1) [9]. This strategy of coexpression has previously been
shown to be more efficient than the use of retroviruses
that depend on internal promoters or alternative splicing
to produce two different gene products [10]. All of these
viruses were derived from the myeloblastosis associated
virus type 1 (MAV-1), the natural helper virus for AMV,
and also included the dominantly selectable neo  gene
[11,12]. In addition, we used an estrogen-inducible form
of the v-Rel protein (v-Rel-ER) so that we could examine
whether Rel activity was required for the maintenance of
transformation in the presence or absence of Myb pro-
teins [13].
Plasmid DNAs containing the replication defective provi-
ruses shown in Figure 1 were each cotransfected along
with the MAV-1 helper virus into primary cultures of
chicken embryonic fibroblasts. Two days later, cells were
treated with G418 to select for the expression of the defec-
tive proviruses, each of which contained the neo gene. As
shown previously, the v-Rel-ER protein was capable of
transforming primary cultures of chicken embryo fibrob-
lasts in an estrogen-dependent fashion (Figure 2). The
control vector containing only the neo gene (N-Cla) had
no effect on fibroblast growth or morphology. As previ-
ously reported, v-Myb alone was incapable of transform-
ing chicken embryonic fibroblasts (not shown).
Somewhat surprisingly, the virus that encoded both the v-
Rel-ER and v-Myb proteins was incapable of causing
Structure of viruses used in this study Figure 1
Structure of viruses used in this study. The long terminal repeats (LTR) were derived from MAV-1. Also shown are the splice 
donor sites (SD), splice acceptor sites (SA) and the internal ribosomal entry sites (IRES) used to express two or three genes 
from a single virus.Molecular Cancer 2006, 5:54 http://www.molecular-cancer.com/content/5/1/54
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fibroblast transformation either in the presence or
absence of estrogen (Figure 2). The v-Myb protein is a
doubly truncated form of the normal c-Myb protein that
has also sustained a number of amino acid substitutions
relative to c-Myb [14]. In order to determine whether the
ability of v-Myb to suppress fibroblast transformation by
v-Rel is a result of these alterations in the v-Myb protein,
we constructed similar viruses that expressed either c-Myb
alone, or both v-Rel-ER and c-Myb (Figure 1). As was
observed with v-Myb, c-Myb itself was incapable of trans-
forming chicken embryonic fibroblasts (not shown). Fur-
thermore, c-Myb was able to completely suppress
transformation by v-Rel-ER in a fashion similar to v-Myb
(Figure 2). These results demonstrate that the v-myb gene,
which is capable of oncogenically transforming macro-
phage precursors and causing monoblastic leukemias in
vivo, can act in an opposing fashion by suppressing
fibroblast transformation by the v-rel oncogene. Further-
more, the c-myb gene which can also cause the outgrowth
of myelomonocytic cells in culture [15,16], behaves simi-
lar to v-myb in suppressing transformation by v-rel.
Myb proteins inhibit the actin cable reorganization 
induced by v-Rel-ER
In addition to the altered cellular morphology induced by
v-Rel-ER in the presence of estrogen, histochemical stain-
ing with fluorescently labeled phalloidin revealed a dra-
matic reorganization of cytoskeletal actin in the presence
but not in the absence of estrogen (Figure 3). The actin
stress fibers seen in control fibroblasts were replaced by a
dense accumulation of cortical actin adjacent to the
plasma membrane in the v-Rel-ER cells in the presence of
estrogen. This change is a hallmark of fibroblast transfor-
mation by the v-rel oncogene [17]. Both the transformed
cellular morphology and the actin redistribution could be
reversed by the withdrawal of estrogen from the culture
medium despite the continued presence of the v-Rel-ER
protein, as previously shown [13]. Consistent with the
inhibition of Rel-induced transformation by c-Myb, no
reorganization of the actin cytoskeleton was observed in
cells infected with the Rel-ER/c-Myb virus even when
estrogen was added to the culture medium (Figure 3).
Similarly, no reorganization of the actin cytoskeleton was
observed in cells infected with the Rel-ER/v-Myb virus
(data not shown).
Protein expression by the dicistronic Rel/Myb viruses
One possible explanation for the failure of the two-onco-
gene viruses to transform chicken embryonic fibroblasts
was that the structure of the IRES viruses somehow pre-
vented translation of the v-Rel-ER fusion protein. To
address this question, cells infected with each of the
viruses shown in Figure 1 were selected with G418 and
total protein lysates of these cells were resolved by dena-
turing polyacrylamide gel electrophoresis. Duplicate gels
were blotted onto nitrocellulose membranes and antibod-
ies specific for either the Rel or Myb proteins were used as
probes (Figure 4). A protein of the molecular weight pre-
dicted for the v-Rel-ER fusion protein was detected in cells
infected with all three viruses encoding this protein. In
contrast, no Rel proteins were detected by immunoblot-
ting in cells infected with a control virus encoding only
the  neo  gene product or in cells infected with viruses
encoding only the v-Myb or c-Myb proteins (Figure 4).
Myb proteins suppress transformation by v-rel Figure 2
Myb proteins suppress transformation by v-rel. Primary cultures of chicken embryo fibroblasts were co-transfected with the 
indicated proviruses and the MAV-1 helper virus. Two days later G418 (200 ug/ml) was applied to select for the expression of 
the neo gene. The morphology of the resulting G418-resistant cells was observed by phase contrast microscopy. The cells 
infected with the Rel-ER virus have a distinct transformed morphology in the presence but not in the absence of estrogen (10-
6 M). This transformed morphology was suppressed by c-myb (Rel-ER-ICB) or v-myb (Rel-ER-IVB).Molecular Cancer 2006, 5:54 http://www.molecular-cancer.com/content/5/1/54
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Myb proteins suppress cytoskeletal reorganization by v-rel Figure 3
Myb proteins suppress cytoskeletal reorganization by v-rel. Primary chicken embryo fibroblasts (CEF) and cells infected with 
the indicated viruses were stained with fluorescent phalloidin to decorate intracellular actin filaments. The cells infected with 
the Rel-ER virus showed a loss of actin cables and increased cortical actin in the presence of estrogen (+E2). Estrogen alone 
had no detectable effect on uninfected cells. Co-expression of c-myb (Rel-ERICB) suppressed this cytoskeletal reorganization.Molecular Cancer 2006, 5:54 http://www.molecular-cancer.com/content/5/1/54
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The v-Myb and c-Myb proteins were clearly detected in
cells infected with all four viruses predicted to encode
these proteins, but not in cells infected with the viruses
encoding only neo or v-Rel-ER without v-Myb or c-Myb.
These results demonstrate that the v-Rel-ER protein was
produced in the presence or absence of v-Myb and c-Myb.
Therefore, the inhibition of v-Rel-ER transformation by v-
Myb and c-Myb does not appear to be due to a failure of
v-Rel-ER protein production.
To investigate the mechanism by which v-myb and c-myb
inhibit fibroblast transformation by v-rel, we first per-
formed a series of transient transfections in the quail QT6
fibroblastic cell line with reporter genes containing either
Myb or Rel binding sites. Transcriptional activation by v-
Myb and c-Myb was unaffected by the presence of v-Rel-
ER (data not shown). We were unable to assay transcrip-
tional activation by v-Rel-ER in avian fibroblasts because,
as previously reported by others, Rel-responsive reporter
genes are highly activated by endogenous Rel-NFkB fam-
ily proteins in the absence of any exogenous Rel [18].
However, the transcription activity of these endogenous
Rel family proteins was unaffected by the presence or
absence of Myb proteins (data not shown). Therefore, we
examined the effects of v-Myb and c-Myb on transcrip-
tional activation by GAL4-Rel fusion proteins [19]. Both a
GAL4-v-Rel and a GAL4-c-Rel fusion protein were able to
activate transcription from a reporter gene containing
GAL4p binding sites. However, this activation was unaf-
fected by either v-Myb or c-Myb (Figure 5). These results
suggest that the Myb proteins do not inhibit transforma-
tion by v-Rel by a transcriptional "sequelching" in which
an excess of one activation domain limits the availability
of a critical coactivator molecule [20]. However, at present
we cannot rule out the possibility that Myb proteins spe-
cifically interfere with transcriptional regulation by Rel
proteins in a manner that cannot be adequately modeled
using GAL4-Rel fusion proteins.
Rel and Myb proteins are associated with one another in 
nuclear extracts
To further investigate the mechanism by which Myb pro-
teins inhibit fibroblast transformation by v-rel, we asked
whether these proteins associate with one another in cells.
For this purpose, QT6 fibroblasts were transfected with
expression vectors for v-Rel-ER and c-Myb, v-Myb, or an
N-terminal fragment of c-Myb containing only the DNA-
binding domain. Lysates of these cells were precipitated
with either anti-Myb or anti-Rel antibodies. The precipi-
tated proteins were resolved by denatured gel electro-
phoresis, transferred to nitrocellulose filters, and then
probed with an anti-Myb antibody (Figure 6). As
expected, all three Myb proteins could be detected follow-
ing immunoprecipitation with anti-Myb antibodies
Myb proteins do not prevent expression of Rel-ER Figure 4
Myb proteins do not prevent expression of Rel-ER. Primary chicken embryo fibroblasts infected with the indicated viruses 
were lysed and analyzed by SDS-PAGE and immunoblotting using either anti-Rel (left panel) or anti-Myb (right panel) antibod-
ies.Molecular Cancer 2006, 5:54 http://www.molecular-cancer.com/content/5/1/54
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(lanes 2, 5, and 8). In addition, both c-Myb and v-Myb
were coprecipitated with anti-Rel antibodies in the pres-
ence of v-Rel-ER (lanes 3 and 6), whereas the c-Myb DNA-
binding domain was not similarly coprecipitated (lane 9).
This coprecipitation was not due to cross-reactivity of Myb
proteins with anti-Rel antibodies nor did it require the
estrogen receptor hormone binding domain, because sim-
ilar coprecipitation was observed in the presence but not
the absence of v-Rel (data not shown). These results dem-
onstrate that the Rel and Myb proteins are capable of
forming a complex in cellular extracts. This complex is
unlikely to be due simply to the bridging of Rel and Myb
proteins by DNA, because the c-Myb DNA binding
domain alone did not coprecipitate with Rel proteins.
Myb genes as inhibitors of oncogenic transformation
Our results demonstrate that v-myb and c-myb, which can
both cause the transformation of hemayopoietic cells, can
also function as suppressors of fibroblast transformation
by the v-rel oncogene. These results suggest that the cell
type in which v-myb or c-myb is expressed appears to deter-
mine whether they function as oncogenes or tumor sup-
pressor genes. Because neither v-Myb nor c-Myb are
normally present in fibroblasts, one hypothesis is that v-
Myb and c-Myb may act as tumor suppressors by domi-
nantly inhibiting the function of B-Myb, a closely related
protein which appears to be ubiquitously expressed in all
vertebrate cells including in fibroblasts [21].
However, v-Myb and c-Myb do not appear to function as
general suppressors of fibroblast transformation. Rather,
the mechanism of transformation also plays a role in
determining whether Myb proteins function as tumor
suppressors, because similar experiments have shown that
fibroblast transformation by the v-myc oncogene of the
MC29 virus is not suppressed by the v-Myb or c-Myb pro-
teins. Furthermore, the myb  and  rel  oncogenes are not
mutually antagonistic in all cells types. In particular, when
hematopoietic yolk sac or bone marrow hematopoietic
cells are infected with viruses containing both v-myb and
v-rel-ER, transformed myeloid cells grow out that are
indistinguishable from cells transformed by v-myb alone
(data not shown).
A model that could explain these data is that v-Rel and the
Myb proteins oppose each other in regulating a common
set of genes that are essential for transformation by v-rel,
whereas the genes essential for transformation by v-myc
are not affected by Myb proteins. In this regard, gene
expression profiling of transformed lymphocytes have
Myb proteins do not inhibit the Rel transcriptional activation domain Figure 5
Myb proteins do not inhibit the Rel transcriptional activation domain. QT6 quail fibroblasts were transfected with a GAL4-rep-
sonsive reporter gene, a plasmid producing the indicated GAL4-Rel fusion (SG-424 is a GAL DNA-binding domain only con-
trol), and a plasmid producing the indicated Myb protein (N-Cla is a control expression vector; DBD is a DNA-binding domain 
only control). Transcriptional activation was measured as previously described [18]. Error bars indicated standard errors of 
the mean.Molecular Cancer 2006, 5:54 http://www.molecular-cancer.com/content/5/1/54
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suggested that at least some genes may be regulated in
common by both Myb and Rel proteins, although many
are not [22]. Our data may also explain why v-myb  is
unique among the known retroviral oncogenes in that it
does not transform fibroblasts – because in fibroblasts v-
myb appears to function as an inhibitor of transformation
rather than as an oncogene. In addition, our findings may
offer some explanation for the paradoxical observation
that elevated levels of c-myb proto-onoocgene expression
are a positive prognostic indicator in human breast cancer
[23].
Conclusion
The v-myb oncogene was discovered because of its ability
to cause monoblastic leukemia in chickens. Altered forms
of the c-myb proto-oncogene cause leukemia and lym-
phoma in birds and mammals. However, neither v-myb
nor c-myb have been shown to oncogenically transform
Co-precipitation of Myb and Rel proteins Figure 6
Co-precipitation of Myb and Rel proteins. Quail fibroblasts co-transfected with expression vectors for Rel-ER and the indicated 
Myb proteins were immunoprecipitated with either anti-Myb or anti-Rel antibodies, then analyzed by SDS-PAGE and immuno-
blotting using an anti-Myb antibody. A sample of the total extract (E) prior to immunoprecipitation was co-electrophoresed as 
a control. c-Myb and v-Myb, but not the c-Myb DNA-binding domain alone were co-precipitated with anti-Rel antibodies.Molecular Cancer 2006, 5:54 http://www.molecular-cancer.com/content/5/1/54
Page 8 of 9
(page number not for citation purposes)
fibroblasts. We report here that v-myb  and c-myb  can
inhibit fibroblast transformation by the v-rel oncogene,
demonstrating that in at least some cellular contexts, v-
myb  and c-myb  can function as tumor suppressors.
Methods
Plasmid constructions
The construction of the N-Cla and N-ICB proviruses has
been described previously [16,24]. The N-IVB provirus
was constructed by cloning the ClaI-resistant IRES-v-myb
fragment of SP73-IVB into N-Cla. SP73-IVB itself contains
the EcoRI/MscI-resistant IRES fragment of the murine
encephalomyocarditis virus (EMCV) and the MscI/XbaI
resistant v-myb fragment of MT7-MYB in a modified SP73
vector in which the entire polylinker was replaced by a
single ClaI site [9,25]. The N-Rel-ER provirus was con-
structed by cloning the small ClaI-resistant fragment of
RCAS-Rel-ER [13] into the ClaI site of a modified N-dGE
vector [26] in which the v-myb coding sequence but not
the splice acceptor site had been removed by digestion
with KpnI and ClaI, fill-in with the Klenow fragment of
DNA polymerase I and insertion of a ClaI linker. The N-
Rel plasmid was constructed in a similar fashion using the
small ClaI-resistant fragment of RCAS-REL [17]. The N-
Rel-ER-IVB and N-Rel-ER-ICB proviruses were created by
ligation of the small ClaI-resistant fragments from N-IVB
(v-myb) or N-ICB (c-myb) into the unique ClaI site of N-
Rel-ER which lies downstream of the Rel-ER open reading
frame.
Cell culture and DNA transfections
Primary chicken embryo fibroblasts (CEF) were prepared
by trypsinizing the bodies of 7 to 9 day old chicken
embryos. These cells were grown in a 37°C, humidified
5% CO2  incubator, in Dulbecco's modified essential
medium (DMEM) supplemented with glucose (4.5 g/l),
1X MEM nonessential amino acids, 1 mM sodium pyru-
vate, 2 mM glutamine, streptomycin (100 ug/ml), penicil-
lin (100 U/ml), 2% heat-inactivated chicken serum
(56°C, 1 hr), and 8% fetal calf serum. QT6 cells were
grown in similar conditions except that 5% fetal calf
serum and no chicken serum were added. Where indi-
cated, estradiol was present at a concentration of 1 uM.
DNA transfections, luciferase assays, and β-galactosidase
assays were performed as described previously [27].
Actin cable staining
CEFs grown in chamber slides were washed with PBS
twice and fixed with lysine-paraformaldehyde-PBS (0.075
M lysine, 0.0375 M sodium phosphate, 2% paraformalde-
hyde, pH 7.4) for 20 minutes at room temperature. Fixed
cells were then washed three times with PBS and stained
with rhodamine-phalloidin (Molecular Probes, Inc) for
25 minutes at room temperature. After staining, the cells
were washed three times with PBS and overlaid with p-
phenylendiamine (PPD)-mounting medium (1%(w/v)
PPD, 90 % glycerol, pH 8.5) and visualized by fluores-
cence microscopy.
Immunoblotting
Cells were washed once with PBS, scraped off the plates in
PBS, centifuged, then lysed in 1X sodium dodecyl sulfate
(SDS)-loading buffer and boiled for 5 minutes. Normal-
ized volumes of lysates were subjected to 10% SDS-poly-
acrylamide gel electrophoresis. Proteins were then
transferred to nitrocellulose membranes (BA-S 83, Sch-
leicher & Schuell). Myb expression was detected using a
mixture of the Myb 2.2 and 2.7 monoclonal murine anti-
bodies [28]. Rel expression was detected using a polyclo-
nal rabbit antiserum SB66 (1:1000 dilution) kindly
provided by Amy Walker and Paula Enrietto. Blots were
developed using either goat anti-mouse IgG or goat anti-
rabbit IgG conjugated to alkaline phosphotase
(Promega), 5-bromo-4-chloro-3 indolylphosphate
(BCIP) and nitroblue tetrazolium (NBT) according to the
manufacturer's instructions.
Immunoprecipitation
Quail fibroblasts co-transfected with expression vectors
for v-Rel-ER or v-Rel and the indicated Myb proteins were
lysed in RIPA buffer without SDS, immunoprecipitated
with either mouse the monclonal Myb 2.2 antibody
which recognizes a region of v-Myb and c-Myb near the
transcriptional activation domain, or the rabbit polyclo-
nal anti-Rel antiserum SB66 using RIPA buffer without
SDS and protein G sepharose [29]. Precipitates were then
analyzed by SDS-PAGE and immunoblotting using the
monoclonal 5E anti-Myb antibody which recognizes the
DNA binding domain [30]. A sample of the total extract
prior to immunoprecipitation was co-electrophoresed as a
control.
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